Recently, an American College of Cardiologists (ACC) Expert Consensus Decision Pathway recommended consideration of PCSK9 inhibitors, after maximising statin therapy and attention to adherence, in several high-risk groups including those with prior CVD and diabetes who have not achieved a ≥50% reduction in LDL-cholesterol and possibly in such individuals who have not achieved a non-HDL-cholesterol level of <2.6 mmol/l [47]. Here, PCSK9 is linked to diabetes mellitus.